Adverum Biotechnologies, Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own1.20% Shs Outstand98.60M Perf Week11.32%
Market Cap118.78M Forward P/E- EPS next Y-1.29 Insider Trans11.74% Shs Float95.11M Perf Month32.91%
Income-155.00M PEG- EPS next Q-0.34 Inst Own65.00% Short Float5.97% Perf Quarter-15.11%
Sales7.50M P/S15.84 EPS this Y-7.60% Inst Trans-3.90% Short Ratio4.81 Perf Half Y-33.71%
Book/sh2.87 P/B0.41 EPS next Y5.80% ROA-33.30% Target Price4.00 Perf Year-66.48%
Cash/sh2.69 P/C0.44 EPS next 5Y- ROE-46.80% 52W Range0.80 - 3.70 Perf YTD-32.95%
Dividend- P/FCF- EPS past 5Y13.90% ROI-46.20% 52W High-68.11% Beta1.10
Dividend %- Quick Ratio12.10 Sales past 5Y38.80% Gross Margin- 52W Low48.36% ATR0.08
Employees188 Current Ratio12.10 Sales Q/Q- Oper. Margin- RSI (14)68.15 Volatility8.50% 8.15%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.20% Profit Margin- Rel Volume0.70 Prev Close1.17
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume1.18M Price1.18
Recom2.70 SMA2016.68% SMA5017.60% SMA200-24.56% Volume830,464 Change0.85%
Jul-23-21Downgrade Cantor Fitzgerald Overweight → Neutral
May-03-21Downgrade SVB Leerink Outperform → Mkt Perform $5
Apr-29-21Downgrade Truist Buy → Hold $30 → $9
Apr-29-21Downgrade RBC Capital Mkts Outperform → Sector Perform $6
Apr-29-21Downgrade Chardan Capital Markets Buy → Neutral $5
Dec-16-20Initiated UBS Neutral $13
Nov-12-20Upgrade Raymond James Underperform → Mkt Perform
Jun-26-20Downgrade Raymond James Mkt Perform → Underperform
May-13-20Initiated RBC Capital Mkts Outperform $24
May-05-20Upgrade SunTrust Hold → Buy $13 → $21
Apr-28-20Initiated Goldman Buy $17
Mar-16-20Initiated SVB Leerink Outperform $17
Feb-10-20Upgrade Chardan Capital Markets Neutral → Buy $20
Feb-10-20Upgrade Cantor Fitzgerald Neutral → Overweight $8 → $21
Oct-15-19Reiterated Chardan Capital Markets Neutral $6 → $10
Sep-13-19Reiterated Chardan Capital Markets Neutral $10 → $6
Jun-14-19Resumed Raymond James Mkt Perform
Nov-02-18Downgrade SunTrust Buy → Hold
Nov-02-18Downgrade Raymond James Outperform → Mkt Perform
Sep-21-18Initiated Cantor Fitzgerald Overweight
Jun-24-22 08:00AM  
Jun-09-22 08:00AM  
Jun-02-22 04:05PM  
May-19-22 08:00AM  
May-18-22 08:11AM  
May-17-22 04:05PM  
May-12-22 04:05PM  
May-11-22 02:51PM  
May-09-22 04:05PM  
May-02-22 04:30PM  
May-01-22 02:15PM  
Apr-19-22 06:00PM  
Apr-07-22 02:50PM  
Apr-06-22 04:05PM  
Mar-29-22 04:05PM  
Mar-17-22 04:05PM  
Mar-02-22 12:11PM  
Feb-28-22 08:00AM  
Feb-15-22 04:22AM  
Feb-07-22 04:05PM  
Jan-06-22 04:05PM  
Jan-04-22 08:00AM  
Jan-01-22 06:02AM  
Dec-21-21 12:42PM  
Dec-06-21 09:00AM  
Nov-30-21 10:25AM  
Nov-17-21 04:51AM  
Nov-04-21 04:05PM  
Oct-09-21 11:17AM  
Oct-05-21 05:17AM  
Oct-04-21 02:31PM  
Oct-03-21 08:14AM  
Oct-01-21 04:00PM  
Sep-27-21 09:00AM  
Aug-23-21 09:00AM  
Aug-19-21 07:05AM  
Aug-06-21 10:19AM  
Aug-05-21 04:05PM  
Jul-22-21 04:05PM  
Jul-19-21 02:49PM  
Jul-01-21 08:00AM  
Jun-28-21 12:00PM  
Jun-24-21 04:05PM  
Jun-21-21 01:22AM  
Jun-07-21 10:00AM  
Jun-01-21 08:00AM  
May-18-21 08:44AM  
May-17-21 12:17PM  
May-12-21 03:17PM  
May-11-21 03:15PM  
May-10-21 10:41AM  
May-06-21 05:15PM  
May-04-21 08:30AM  
May-03-21 06:07AM  
May-01-21 03:26PM  
Apr-29-21 02:58PM  
Apr-28-21 04:01PM  
Apr-26-21 09:00AM  
Apr-22-21 05:00PM  
Apr-21-21 08:00AM  
Apr-19-21 04:10PM  
Apr-16-21 08:05AM  
Apr-15-21 08:00AM  
Apr-08-21 09:39AM  
Mar-30-21 09:00AM  
Mar-18-21 04:00PM  
Mar-17-21 05:10PM  
Mar-05-21 08:30AM  
Mar-02-21 07:31AM  
Mar-01-21 05:25PM  
Feb-22-21 04:00PM  
Feb-18-21 04:00PM  
Feb-10-21 04:49PM  
Feb-02-21 09:00AM  
Jan-21-21 11:02PM  
Jan-11-21 12:00PM  
Jan-08-21 08:49AM  
Jan-07-21 11:57AM  
Jan-05-21 09:00AM  
Dec-21-20 10:23AM  
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seyedkazemi SetarehChief Development OfficerMay 23Buy0.8420,00016,80020,600May 24 04:47 PM
D'Souza RupertChief Financial OfficerMay 17Buy0.8310,0008,27220,850May 17 06:28 PM
Beckman RichardChief Medical OfficerMay 17Buy0.8210,0008,22810,000May 19 07:43 PM
Svoronos DawnDirectorMay 16Buy0.8530,00025,57850,000May 18 04:43 PM
D'Souza RupertChief Financial OfficerMay 13Buy0.8610,0008,58510,850May 17 06:28 PM
Fischer LaurentCEO, President and DirectorApr 20Buy1.1125,00027,800762,462Apr 22 05:00 PM
Soparkar PeterSee Remarks sectionApr 19Buy1.1421,92524,994280,556Apr 20 04:35 PM
Fischer LaurentCEO, President and DirectorDec 09Buy1.8514,32326,498737,462Dec 10 05:26 PM
Fischer LaurentCEO, President and DirectorDec 08Buy1.7910,67719,112723,139Dec 10 05:26 PM
Soparkar PeterSee Remarks sectionDec 08Buy1.9125,00047,750258,631Dec 10 05:26 PM
Scopa James PaulDirectorNov 15Sale2.1850,000109,0003,334Nov 17 04:38 PM
Clark JulieChief Medical OfficerSep 30Sale2.174,76610,342164,723Oct 04 05:36 PM